Symptomatic management of multiple sclerosis in primary care
|
|
- Brianne Pierce
- 8 years ago
- Views:
Transcription
1 summarising clinical guidelines for primary care Endorsed by Symptomatic management of multiple sclerosis in primary care This guideline was developed by a multidisciplinary expert panel: Rashid W et al with the support of a grant from both Bayer Healthcare and Novartis. The Multiple Sclerosis Society has endorsed this working party guideline. See inside front cover for full disclaimer.
2 The development of this working party guideline has been supported by a grant from both Bayer Healthcare and Novartis. The Multiple Sclerosis Society has endorsed this working party guideline. This guideline has been developed by MGP Ltd, the publisher of Guidelines, and the Working Party was convened by them. The guideline was developed by a multidisciplinary expert panel decided by the Chair. This working party guideline has been funded by both Bayer Healthcare and Novartis, but neither of the sponsors had any influence over the content of the guideline. Bayer Healthcare and Novartis were sent the scope and background reading documents for their information, however, final decisions rested with the Multiple Sclerosis Society and the Chair. The content is independent of any sponsorship, but has been reviewed and endorsed by the Multiple Sclerosis Society.* * Please see the MS Society working with industry policy at MGP 2013 Date of preparation: October 2013
3 Symptomatic management of multiple sclerosis in primary care Working Party Rashid, Cox, Jackson, McFadden, Merriman & Vernon This guideline was developed by a multidisciplinary expert panel: Rashid W et al with the support of a grant from both Bayer Healthcare and Novartis. The Multiple Sclerosis Society has endorsed this working party guideline. See page 7 for full disclaimer. Background The cause of MS is currently unknown. The condition usually becomes apparent in early adult life, being diagnosed most often in people aged years in whom it is the most common cause of neurological disability and only rarely in young children and adults aged >65 years Multiple sclerosis affects both sexes, although women are three times as likely to develop the disease as men There are four different patterns of MS see full guideline for details Diagnosis Diagnosis of MS is difficult, as there is no simple diagnostic test, each patient has a different pattern of disease and symptoms, none of the symptoms occur only in patients with MS, and at least two episodes are needed before a definitive diagnosis of MS can be made (until then the patient might be said to have clinically isolated syndrome [CIS]) Early treatment can be beneficial for long-term prognosis, so it is important for primary care HCPs to identify patients with symptoms suspicious or indicative of MS Bear in mind the typical patient profile for MS but do not limit suspicion to such patients: Female Young (20 50 years) No other significant comorbidity/ medications Post-partum (or no children in the presence of urinary dysfunction) The following symptoms indicate the need for immediate referral to a specialist neurologist: Optic neuritis Transverse myelitis (motor weakness, sensory disturbance, sphincter disturbance) The following symptoms indicate the need for referral on a less urgent basis, depending on rate of accumulation and severity of symptoms (usually within 6 weeks): Evolving sensory problems Brainstem/cerebellar symptoms Sphincter problems without other cause (e.g. post-partum) Evolving neurological problems (particularly ataxia and spastic paraparesis) For patients with the following symptoms, watch and wait for about 6 weeks with a suspicion of MS in mind (consider referral if symptoms are not resolving or new symptoms emerge): Sensory problems excluding other causes Vertigo (look out for evolution/ other brainstem signs) Facial pain Pain in association with other neurological symptoms The following symptoms when present in isolation are unlikely to result from MS: Fatigue Pain Anxiety 3
4 Bowel disturbance in the absence of urinary dysfunction Dizziness Trigeminal neuralgia (except in atypical context; refer to NICE CG 96) Cognitive deficits Almost every patient with a recent diagnosis of MS will see their GP soon after diagnosis and will often have many questions: Patients do not always want to know everything, especially in the early stages when they may feel overwhelmed, so give them essential information including points of contact, information leaflets, and details of patient support organisations Ask them to notify you if they develop any new symptoms, have any questions or concerns, or if they feel that they need additional support Ensure patients with a confirmed diagnosis of MS are referred to secondary care for appropriate therapy, rehabilitation, and specialist assessment Treatment options for the major symptoms in MS Once MS has been confirmed by a neurologist, continue to exclude other possible causes of symptoms before treatment Pain Pain is common, occurring in 30 90% of patients with MS; it often evolves over time Patients often describe the MS hug a feeling of tightness around the trunk that is associated with transverse myelitis Non-pharmacological options can be useful: Light and loose clothing, e.g. silk, can help with allodynia Changes to footwear can help with foot pain Identify and avoid trigger factors, where possible Pain is often secondary to other symptoms, such as fatigue, gait problems, and lifestyle issues Transcutaneous electrical nerve stimulation (TENS) Topical and oral pharmacological agents may be used to manage pain in MS: Topical treatments are used firstline for focal pain and as adjuncts to pharmacological agents: Lidocaine plasters Capsaicin make patients aware of the potential associated discomfort and advise patients to check for skin abrasions and to wear gloves when applying Some patients report benefits with topical rubefacient heat rubs Oral drugs are the main approach for pain: Basic analgesics can be useful for relief of general pain, including neuropathic pain and pain after beta-interferon injections, using (in order of escalation) paracetamol, ibuprofen, cocodamol, and tramadol Tricyclic antidepressants are particularly useful for patients with sleep problems and neuropathic pain. Low doses should be used initially, with slow uptitration as needed and patients should be advised why these drugs are being prescribed Duloxetine, which is indicated for neuropathic pain in patients with diabetes, is a useful alternative Anticonvulsant (antiepileptic) medications are reported to be useful, although clinical evidence is weak: Gabapentin is the traditional first choice, but NICE recommends first-line pregabalin Minimise side-effects with a low starting dose (100 mg gabapentin or 50 mg pregabalin three times daily) and slow uptitration (every 2 weeks in small increments, or more quickly for pregabalin if pain is severe) Pregabalin does have abuse potential in comparison to gabapentin 4
5 Referral No guidance is available on switching between gabapentin and pregabalin, so the working party group recommend concurrent downtitration/uptitration Carbamazepine is the drug of choice for trigeminal neuralgia Lamotrigine is well tolerated, has a mood-stabilising effect, and provides occasional benefit, although there is no firm evidence in neuropathic pain Opiates can be helpful for neuropathic pain but side-effects including constipation and sedation are a concern: Fentanyl patches Oral tramadol and oxycodone Stronger opioids should be prescribed by the specialist pain team only Refer to pain clinic if background or breakthrough pain is causing functional or social deficits, if adherence is poor due to side-effects, or for chronic pain syndrome Refer to neurologist for facial pain, dermatomal pain, and distal lower leg pain due to possible nerve entrapment Depression and anxiety Clinical depression is more common in patients with MS than in patients with other chronic diseases: Lifetime prevalence of major depressive disorder in patients with MS is 50% Suicide is 7.5-fold more common in patients with MS than the general population Depression affects carers as well as patients Diagnosis and management Manage depression as for any patient, while bearing in mind the high risk of severe depression and suicide in patients with MS: MS nurses provide valuable support and can coordinate with GPs Consider early referral to the community mental health team/psychological services Non-pharmacological options: Online and face-to-face cognitive behavioural therapy (CBT) Talking therapy Neurologists can provide additional expert support Fatigue Identify and manage modifiable causes, including sleep hygiene, depression, thyroid dysfunction, anaemia, infection, vitamin B12 and folate deficiency, vitamin D deficiency, lifestyle/work pattern, support, and drugs Patients should be advised about selfmanagement programmes, such as FACETS if fatigue still persists, refer to other members of the MDT and liaise with the neurology team for further specialist advice Spasticity Look for and manage concurrent conditions that could be causing spasticity, including infection (particularly urinary tract infection [UTI]), constipation, skin integrity issues/ pressure sores, and malnourishment Assess lifestyle for helpful modifications Pharmacological options: The NICE guideline on MS provides useful advice on options for the management of spasticity, for example with baclofen, cannabis-based oromucusal spray, gabapentin, and tizanidine Cannabis-based oromucusal spray is a licensed treatment for spasicity in patients with MS. However, it has not undergone a formal NICE technology appraisal Refer the patient to the neurologist or MS rehabilitation team if two different agents fail to control spasticity 5
6 Motor function impairment Rule out other causes of motor weakness, such as spinal cord injury and stroke Non-pharmacological approaches include adapting the patient environment, e.g. using walking aids, lifestyle modifications, and functional electrical stimulation Refer to local therapy services for specialist support Refer to neurologist if patients experience rapid progression or acute onset of new symptoms, or fail to respond to non-pharmacological options Cognitive function impairment Cognitive dysfunction is common, affecting around 50% of patients,even those with early MS. It often presents as problems with executive function, organisational ability, and sequencing, but other symptoms can develop over time. It is not related to disease severity or progression. Check that the patient has true cognition problems rather than depression/anxiety Have medication reviewed to minimise iatrogenic cognitive losses, look out for anti-cholinergics and sedating agents Check thyroid function, vitamin B12 and folate levels, and treponemal serology Rule out other causes of cognitive dysfunction, which can still develop in MS Rule out UTI, which is a common cause of cognition problems Liaise with the MS nurse Refer to the neurologist or specialist MS team if the patient experiences: Acute worsening of cognition in the absence of underlying causes, e.g. UTI Rapid progression of cognitive dysfunction or signs of psychosis Cognitive dysfunction in the early stages of MS Bowel and bladder problems Bladder problems are common in people with MS but can be effectively managed. Some people with MS will not experience any problems with the bowel, but constipation and bowel incontinence may affect people with MS at some stage Urinary incontinence (UI) affects about 75% of people with MS: May be related to bladder overactivity or incomplete bladder emptying: Detrusor muscle instability is more common in early MS; as MS progresses, efficiency of bladder emptying reduces Can be due to causes other than MS: In men UI may result from prostatic disease In women UI often follows childbirth May develop due to medicines prescribed for fatigue, anxiety, and depression Diagnosis: Exclude UTI Refer for post-void scan (via continence advisory service or MS specialist nurse) Management varies depending on whether the patient has bladder overactivity or incomplete bladder emptying: The NICE guideline on management of lower urinary tract dysfunction in neurological disease is a useful guide Refer for neurological opinion if the patient has frequent UTIs or UI is resistant to treatment, or if UI is associated with loss of sensation Most patients with MS experience constipation; diarrhoea also occurs but is often secondary to constipation: Bowel dysfunction rarely develops before urinary problems in patients with MS MS nurses can provide advice on lifestyle modifications including dietary modifications, exercise, and regarding fluid intake 6
7 Impact on sex, intimacy, and relationships Sexual dysfunction is common, affecting 50 90% of men with MS and 40 80% of women Managing relapses A relapse is a new episode of symptoms or disability in the absence of fever or infection, which lasts at least 24 hours, is a neurological disturbance typical of MS, and occurs 30 days since the start of a previous episode: Rule out infections and other reasons for worsening of symptoms Patients may be on any of the medications listed below Only certain forms of beta interferon may be used for secondary progressive MS with relapses, with other therapies used only for relapsing-remitting MS Steroids There is no role for long-term maintenance steroids, but short courses of high-dose steroids are used to hasten recovery from relapse Seek advice from the neurology/ms team before prescribing steroids for MS relapses Disease modifying therapies (DMTs) Only certain forms of ß-interferon may be used for secondary progressive MS with relapses, as per UK guidelines, with other therapies used only for relapsing-remitting MS DMTs are prescribed by the hospital MS team contact the specialist MS team and/or MS nurse for information about these drugs None of these therapies are licenced for pregnancy Stopping treatment The decision to stop treatment will always be made by a member of the MS team; however, GPs can re-refer back to the team if you are concerned Palliative care Refer to palliative care if patients are not responding to usual symptom management and the following symptoms are progressing: Reduced mobility Speech and swallowing difficulties Pneumonia Aspiration Hospital admissions Reduction in function Breathing difficulties Pain Spasms and spasticity DMTs reduce the frequency and severity of relapses: ß-interferon Fingolimod Glatiramer acetate Natalizumab sponsor about this working party guideline... This guideline has been developed by MGP Ltd, the publisher of Guidelines, and the Working Party was convened by them. The guideline was developed by a multidisciplinary expert panel decided by the Chair. This working party guideline has been funded by both Bayer Healthcare and Novartis, but neither of the sponsors had any influence over the content of the guideline. Bayer Healthcare and Novartis were sent the scope and background reading documents for their information, however, final decisions rested with the Multiple Sclerosis Society and the Chair. The content is independent of any sponsorship, but has been reviewed and endorsed by the Multiple Sclerosis Society. working party members Waqar Rashid (Chair, Consultant Neurologist), Adrienne Cox (Multiple Sclerosis Nurse), Katy Jackson (Head of Prescribing and Medicines Commissioning), Estelle McFadden (GPwSI Neurology), Honor Merriman (General Practitioner), Karen Vernon (Multiple Sclerosis Nurse) further information call MGP Ltd ( ) for a copy of the full guideline October
8 MGP 2013
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationNHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
More informationNational Hospital for Neurology and Neurosurgery. Managing Spasticity. Spasticity Service
National Hospital for Neurology and Neurosurgery Managing Spasticity Spasticity Service If you would like this document in another language or format, or require the services of an interpreter please contact
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationVoting for your top research questions Survey
MS Priority Setting Partnership Voting for your top research questions Survey Prioritising important research questions for multiple sclerosis a partnership between people affected by MS and healthcare
More informationManaging the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner
Managing the Symptoms of Multiple Sclerosis Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner What is Multiple Sclerosis An autoimmune disease that affects the central nervous system (CNS) The immune
More informationPCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationChoices Drug Therapies
Choices Drug Therapies There are many prescription drugs available to treat MS. There are disease modifying drugs that affect the long-term course of MS and other medications to treat a particular symptom.
More informationMedications for chronic pain
Medications for chronic pain When it comes to treating chronic pain with medications, there are many to choose from. Different types of pain medications are used for different pain conditions. You may
More informationSpine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015
Spine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015 Introduction Multiple sclerosis (MS) affects nerves in the brain and spinal cord, causing a wide range of symptoms including
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationRegistered Charity No. 5365
THE MULTIPLE SCLEROSIS SOCIETY OF IRELAND Dartmouth House, Grand Parade, Dublin 6. Telephone: (01) 269 4599. Fax: (01) 269 3746 MS Helpline: 1850 233 233 E-mail: mscontact@ms-society.ie www.ms-society.ie
More informationGwen Griffith Clinical Nurse Specialist Bolton NHS foundation Trust
Gwen Griffith Clinical Nurse Specialist Bolton NHS foundation Trust Overview Setting the Scene Beginning of the journey & specialist nurse role Why people with MS experience bladder problems MS and the
More informationSymptomatic Treatment of MS Symptomatic treatments approved for use in patients with MS
Symptomatic Treatment of MS Symptomatic treatments approved for use in patients with MS Generic name Market name Symptoms Indicated Baclofen Lioresal Spasticity, cramps, stiffness Tizanidine Zanaflex Same
More informationNHS FORTH VALLEY Multiple Sclerosis Service Management of MS Relapses
NHS FORTH VALLEY Multiple Sclerosis Service Management of MS Relapses Approved 22/06/2010 Version Version 2 Date of First Issue 2002 Review Date 10/05/2016 Date of Issue 01/02/2010 EQIA Yes 22.06.10 Author
More informationSymptoms can come and go; some are much more responsive to treatment whereas others are more difficult to manage.
Choices Symptoms MS-UK believes that based on experience, people cope best when they look at what is happening, rather than what might be. MS can cause a long list of symptoms. This list is not exhaustive
More informationMellen Center for Multiple Sclerosis
Mellen Center Cleveland Clinic Marie Namey, RN, MSN, MSCN Mellen Center Cleveland Clinic Cleveland, OH Home of. Mellen Center for Multiple Sclerosis Mellen Center Mission The Mellen Center remains committed
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationDrug treatments for neuropathic pain
Understanding NICE guidance Information for people who use NHS services Drug treatments for neuropathic pain NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases
More informationClinical Audit: Prescribing antipsychotic medication for people with dementia
Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home
More informationSample Treatment Protocol
Sample Treatment Protocol 1 Adults with acute episode of LBP Definition: Acute episode Back pain lasting
More information06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
More informationKnowledge Brochure Series MS & SYMPTOM MANAGEMENT
Knowledge Brochure Series MS & SYMPTOM MANAGEMENT Identifying your multiple sclerosis (MS) symptoms 1 A chronic disease like MS can cause a number of different symptoms and spotting yours is the first
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationSativex. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Sativex Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Sativex Date of issue: July 2010 Review date: July 2011 Contents 1. Introduction 1 2. What is Sativex?
More informationChoices Primary Progressive MS (PPMS)
Choices Primary Progressive MS (PPMS) What is primary progressive MS? Approximately 10% of people with MS worldwide are told they have primary progressive MS a form of MS where from the very first symptoms,
More informationHow To Treat An Elderly Patient
1. Introduction/ Getting to know our Seniors a. Identify common concepts and key terms used when discussing geriatrics b. Distinguish between different venues of senior residence c. Advocate the necessity
More informationLow back pain. Quick reference guide. Issue date: May 2009. Early management of persistent non-specific low back pain
Issue date: May 2009 Low back pain Early management of persistent non-specific low back pain Developed by the National Collaborating Centre for Primary Care About this booklet This is a quick reference
More informationClinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
More informationUnderstanding Relapse in Multiple Sclerosis. A guide for people with MS and their families
Understanding Relapse in Multiple Sclerosis A guide for people with MS and their families Introduction You have been given this booklet because you have been diagnosed with Multiple Sclerosis (MS) and
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationPOST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationMultiple sclerosis (MS)
Multiple sclerosis (MS) Summary Multiple sclerosis (MS) is an incurable disease of the central nervous system that can affect the brain, spinal cord and optic nerves. The effects of MS are varied and unpredictable,
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationGuidance on competencies for management of Cancer Pain in adults
Guidance on competencies for management of Cancer Pain in adults Endorsed by: Contents Introduction A: Core competencies for practitioners in Pain Medicine B: Competencies for practitioners in Pain Medicine
More informationMellen Center Approaches: Pain in Multiple Sclerosis
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Pain in Multiple Sclerosis How often do MS patients have pain? The point prevalence of
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationCommissioning Policy: Disease Modifying Therapies for patients with Multiple Sclerosis (MS).
Commissioning Policy: Disease Modifying Therapies for patients with Multiple Sclerosis (MS). Reference No: Version: 1 Ratified by: EMSCGP029V1 EMSCG Board Date ratified: 25/09/2009 Name of originator/author:
More informationSupporting MS-Related Disability Claims to Private Insurers: The Physician s Role
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals
More informationA Guide to pain relief medicines For patients receiving Palliative Care
A Guide to pain relief medicines For patients receiving Palliative Care 1 Which pain medicines are you taking? Contents Page No. Amitriptyline 8 Codeine 9 Co-codamol 10 Co-dydramol 11 Diclofenac (Voltarol
More informationPatient Sticker Multiple Sclerosis Ambulatory Emergency Care Pathway
Multiple Sclerosis Ambulatory Emergency Care Pathway 1 Consultant: Dr M Oldfield Consultant: Dr D Harris Lead Nurse: Catie Paterson Ambulatory Emergency Care (AEC) Unit Patient From ED (Emergency Department)
More informationMichelle H. Cameron, M.D., P.T., M.C.R. Portland VA MS Center of Excellence- West, and Oregon Health & Science University
Michelle H. Cameron, M.D., P.T., M.C.R. Portland VA MS Center of Excellence- West, and Oregon Health & Science University Ileana Howard, M.D. VA Puget Sound, Seattle, WA and University of Washington PVA
More informationFemale Urinary Disorders and Pelvic Organ Prolapse
Female Urinary Disorders and Pelvic Organ Prolapse Richard S. Bercik, M.D. Director, Division of Urogynecology & Reconstruction Pelvic Surgery Department of Obstetrics, Gynecology & Reproductive Sciences
More informationMS Essentials. Pain and sensory symptoms. This publication is available in large print and audio CD Call 020 8438 0999 or email shop@mssociety.org.
Second edition Reviewed and reprinted May 2014 17 MS Essentials For people living with MS This publication is available in large print and audio CD Call 020 8438 0999 or email shop@mssociety.org.uk Pain
More informationVictorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management
Victorian Nurse Practitioner Project Phase 4, Round 4.11 - Chronic Disease Management Eastern Health Multiple Sclerosis Nurse Practitioner Service Model April 2014 Prepared by Jodi Haartsen and Deanna
More informationDepression & Multiple Sclerosis
Depression & Multiple Sclerosis Managing specific issues Aaron, diagnosed in 1995. The words depressed and depression are used so casually in everyday conversation that their meaning has become murky.
More informationUrinary Incontinence FAQ Sheet
Urinary Incontinence FAQ Sheet Are you reluctant to talk to your doctor about your bladder control problem? Don t be. There is help. Loss of bladder control is called urinary incontinence. It can happen
More informationCoping with Symptoms of Multiple Sclerosis
Coping with Symptoms of Multiple Sclerosis Josée Poirier B. Sc. Nursing, MSCN Outline What Is a Pseudo exacerbation? Awareness Advancement of Treatments Treatment of Symptoms Uhthoff s Phenomenon What
More informationBladder and Bowel Assessment Ann Yates Director of Continence Services. 18/07/2008 Cardiff and Vale NHS Trust
Bladder and Bowel Assessment Ann Yates Director of Continence Services Types of continence problems Bladder Stress incontinence Urgency and urge Incontinence Mixed incontinence Obstructive incontinence
More informationMultiple Sclerosis (MS)
Multiple Sclerosis (MS) Purpose/Goal: Care partners will have an understanding of Multiple Sclerosis and will demonstrate safety and promote independence while providing care to the client with MS. Introduction
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationWebinar title: Know Your Options for Treating Severe Spasticity
Webinar title: Know Your Options for Treating Severe Spasticity Presented by: Dr. Gerald Bilsky, Physiatrist Medical Director of Outpatient Services and Associate Medical Director of Acquired Brain Injury
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationSOUTH TAMPA MULTIPLE SCLEROSIS CENTER
SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/CARE GIVER QUESTIONNAIRE DEMOGRAPHIC INFORMATION Patient's Name: City: State: Zip Code: Phone: Marital Status: Spouse/Care Giver Name: Phone (H) (W) Occupation:
More informationhttp://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387! 388! http://my.fresnounified.org/personal/lygonza/gonzalez/neuron/neuron5synapse%20communication.png!! http://www.urbanchildinstitute.org/sites/all/files/databooks/2011/ch15fg25communication5between5neurons.jpg!!
More informationRehabilitation and the role of carers
Rehabilitation and the role of carers Dr Jacinta Morgan Consultant in Rehabilitation Medicine National Clinical Lead, Rehabilitation Medicine Programme (HSE CSPD) EMSP Spring Conference Gibson Hotel Dublin,
More informationNeurological and Trauma Impairment Set Version 10
Neurological and Trauma Impairment Set Version 10 Admission/Discharge - Neurological + Trauma Impairment Set Version 10 (Please circle reason for assessment) Name: Severity scores - extent to which deficit
More informationNew perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
More informationOpioids in Palliative Care- Patient Information Manual
Version 2.0 with MST example Introduction The following pages explain what opioids are and what we think you may want to know about them. There is quite a lot of information here, most of it is based on
More informationTreating symptoms. An introduction to. Everyone diagnosed with MS can get treatment for their symptoms. The symptoms of MS. Who can get treatment?
Everyone diagnosed with MS can get treatment for their symptoms This resource is an introduction to the treatments that are available. The symbol will point you to further resources. An introduction to
More informationRelapsing remitting MS
An introduction to Relapsing remitting MS What does it mean when you are diagnosed with relapsing remitting MS? There are three main types of MS: relapsing remitting MS, primary progressive MS and secondary
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationUrology Nurse Practitioner Urology Research Nurse Australian Prostate Cancer Research Centre Epworth November 18, 2011
Urology Nurse Practitioner Helen Crowe Urology Nurse Practitioner Urology Research Nurse Australian Prostate Cancer Research Centre Epworth November 18, 2011 Nurse Practitioner Registered nurse who has
More informationLow Back Pain Protocols
Low Back Pain Protocols Introduction: Diagnostic Triage And 1. Patient Group Adults aged 18 years and over with routine low back problems. Patients who have had recent surgery should be referred directly
More informationOveractive Bladder (OAB)
Overactive Bladder (OAB) Overactive bladder is a problem with bladder storage function that causes a sudden urge to urinate. The urge may be difficult to suppress, and overactive bladder can lead to the
More informationBetaferon (interferon beta 1b)
Betaferon (interferon beta 1b) What is Betaferon? Betaferon (interferon beta-1b) is a type of medicine known as an interferon, which is used to treat MS. Interferons are proteins found naturally in the
More informationQuality Measures for Long-stay Residents Percent of residents whose need for help with daily activities has increased.
Quality Measures for Long-stay Residents Percent of residents whose need for help with daily activities has increased. This graph shows the percent of residents whose need for help doing basic daily tasks
More informationClinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
More informationDepression & Multiple Sclerosis. Managing Specific Issues
Depression & Multiple Sclerosis Managing Specific Issues Feeling blue The words depressed and depression are used so casually in everyday conversation that their meaning has become murky. True depression
More information6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S.
High Prevalence and Incidence Prevalence 85% of Americans will experience low back pain at some time in their life. Incidence 5% annual Timothy C. Shen, M.D. Physical Medicine and Rehabilitation Sub-specialty
More informationThe Role of the Haematology Specialist Nurse. Catherine Chapman RN. BSc (Hons)
The Role of the Haematology Specialist Nurse Catherine Chapman RN. BSc (Hons) Key Roles Information Support Advice Patient advocate Education Coordination of care Information Patient Family Carers Health
More informationUnderstanding Relapse in Multiple Sclerosis
Understanding Relapse in Multiple Sclerosis A guide for people with MS and their families Introduction Relapses are very common in MS and largely unpredictable in terms of how often they occur, how severe
More informationMultiple sclerosis and pain
9 Multiple sclerosis and pain 2ND EDITION Multiple Sclerosis Society of New Zealand CONTENTS Introduction-------------------------------------------------------------------------------------------3 How
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationFibromyalgia. Factsheet
Factsheet Fibromyalgia Fibromyalgia can cause similar symptoms to multiple sclerosis (MS) including muscle weakness and pain in the arms and legs. In fibromyalgia, the pain is musclespecific, and not in
More informationHalloween Costume Ideas - The Ultimate Party Planning Formula
Patient Type 2 Diabetes Aboriginal Health Workers Audiologists Chiropractors Diabetes Educators Dietitians Exercise Physiologists Mental Health Nurses Mental Health Social Workers Occupational Therapists
More informationMultiple sclerosis the quick guide. Second edition December 2011
Multiple sclerosis the quick guide Second edition December 2011 About this information It s for any staff who care for people affected by multiple sclerosis (MS) It s a quick guide it gives an instant
More informationAbstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
More informationALL ABOUT SPASTICITY. www.almirall.com. Solutions with you in mind
ALL ABOUT SPASTICITY www.almirall.com Solutions with you in mind WHAT IS SPASTICITY? The muscles of the body maintain what is called normal muscle tone, a level of muscle tension that allows us to hold
More informationTension-type headache Non-pharmacological and pharmacological treatment
Danish Headache Center Tension-type headache Non-pharmacological and pharmacological treatment Lars Bendtsen Associate professor, MD, PhD, Dr Med Sci Danish Headache Center, Department of Neurology Glostrup
More informationBladder Health Promotion
Bladder Health Promotion Community Awareness Presentation Content contributions provided by the Society of Urologic Nurses (SUNA) National Association for Continence (NAFC) Simon Foundation for Continence
More informationBotox (Botulinum Toxin) injections into the bladder
York Teaching Hospital NHS Foundation Trust Botox (Botulinum Toxin) injections into the bladder Information for patients, relatives and carers Department of Urology York Teaching Hospital NHS Foundation
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationREHABILITATION MEDICINE by PROFESSOR ANTHONY WARD
REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD What is Rehabilitation Medicine? Rehabilitation Medicine (RM) is the medical specialty with rehabilitation as its primary strategy. It provides services
More informationMany people with MS use some form of conventional medical treatment, and many people also use complementary and alternative medicine (CAM).
Complementary and alternative medicine (CAM) CAM therapies can generally be divided into the following categories: Biologically based therapies (eg, dietary supplements, diets, bee venom therapy, hyperbaric
More informationSECTION B THE SERVICES COMMUNITY STROKE REHABILITATION SPECIFICATION 20XX/YY
SECTION B THE SERVICES COMMUNITY STROKE REHABILITATION SPECIFICATION 20XX/YY SECTION B PART 1 - SERVICE SPECIFICATIONS Service specification number Service Commissioner Lead Provider Lead Period Date of
More informationPatient Group Input to CADTH
Patient Group Input to CADTH Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group/author of submission Patient group s contact information:
More informationAntipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers
SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this
More informationInformation for patients. Sex and Incontinence. Royal Hallamshire Hospital
Information for patients Sex and Incontinence Royal Hallamshire Hospital Why is sex important? We may choose to be sexual, regardless of our age, physical status or stage of life. Those with health problems
More informationProfessional resources First edition June 2009. Translating the NICE and NSF guidance into practice A guide for occupational therapists
Professional resources First edition June 2009 Translating the and NSF guidance into practice A guide for occupational therapists 2 Foreword Multiple sclerosis (MS) is the most common disabling neurological
More informationClinical Guideline. Low Back Pain Orthopaedics. Princess Alexandra Hospital Emergency Department. 1 Purpose. 2 Background
Princess Alexandra Hospital Emergency Department Clinical Guideline Orthopaedics Review Officer: Katherine Isoardi Version no: 1 Approval date: 18/03/2015 Review date: 18/03/2017 Approving Officer Dr James
More informationMULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs
More informationDecisions relating to Multiple Sclerosis treatments
10 October 2014 Decisions relating to Multiple Sclerosis treatments PHARMAC is pleased to announce that, from 1 November 2014, it will: list fingolimod (Gilenya); list natalizumab (Tysabri); and change
More informationUrinary Incontinence in Women. Susan Hingle, M.D. Department of Medicine
Urinary Incontinence in Women Susan Hingle, M.D. Department of Medicine Background Estimated 13 million Americans with urinary incontinence Women are affected twice as frequently as men Only 25% will seek
More information